CST BLOG: Lab Expectations

The official blog of Cell Signaling Technology (CST), where we discuss what to expect from your time at the bench, share tips, tricks, and information.

Can I accelerate my ELISA results?

Read More
All Posts

Running an ELISA can be a pain. Identifying pairs for an ELISA is a tedious business, and that’s before developing and validating the ELISA assay itself. Using a kit can simplify the process, but at what cost? Will that kit hinder reproducibility by introducing lot-to-lot variability over the course of my project’s lifetime? Many kits still require numerous reagent addition, incubation, and wash steps that add hands-on time and complexity to your assay.

And if you’ve felt this pain before, we hear you. We’re always trying to find ways to make life simpler for those in the lab. So, we’ve addressed some of these issues head-on by developing FastScan™ ELISA.

18-ELS-47247 FastScan Featured copyThese ready-to-use enzyme-linked immunosorbent assay (ELISA) kits let you move through the research and discovery phases faster. We’ve identified optimal antibody pairs and done the assay development and validation up front to make sure your results are accurate across the lifetime of your discovery project—from target validation through preclinical phases. Even if that project takes longer than anticipated, there’s no need to sweat it!

The use a simple, 90-minute protocol that easily integrates into your current processes, streamlines assay transfer, and lets you rapidly detect targets. Maybe you can add a few extra coffee breaks into your day. We won’t tell if you don’t.

These kits are available for both phosphorylation-specific and total protein options and come with integrated controls, so your day-to-day results stay on track. They also cover disease targets in cell biology, epigenetics, immuno-oncology, and neuroscience and include a wide selection of assays to measure key cellular signaling proteins.

FastScan ELISA Kits

Get ELISA Results in 90 Minutes

Sounds great, but how does it work, right?

The simple FastScan ELISA protocol reduces your hands-on time by half and incubation times by 3X. Your sample, along with capture and detection antibodies, are added to the precoated microwell, incubated for ~1 hour, and then washed three times. Next, substrate is added and incubated for 10 to 15 minutes before stop solution is added, followed by signal measurement. The results you need in only 90 minutes!

18-ELS-47247 FastScan Fig 2

How FastScan ELISA Technology Works

FastScan ELISAs use a less complex, solution-based assay format with fewer overall steps, so time-to-results is much faster compared to conventional protocols. You’ll also get consistent results across biological sample types with sensitivity that’s comparable to or better than traditional sandwich ELISA.

18-ELS-47247 FastScan Fig 1

  • Sample “target” is incubated with a capture antibody conjugated with a proprietary tag and a second detection antibody linked to horse radish peroxidase (HRP).
  • The entire complex is immobilized to a microwell via an anti-tag antibody.
  • Wells are washed, followed by enzymatic reaction and readout of target analyte quantity by colorimetric detection.

Results You Can Trust

CST scientists preselect antibody pairs based on their optimal activity in solution phase. FastScan ELISA kits, along with the recombinant antibodies and reagents that come in each kit, are also developed, produced, and rigorously validated in-house. So, you can be absolutely certain of accuracy, lot-to-lot reproducibility, and consistency of results between users and sample types.

Learn more about FastScan ELISA.

Chris Sumner
Chris Sumner
Chris Sumner was the Editor-in-Chief of Lab Expectations. When he's not reading/writing about curing disease, he's hiking in the woods, playing guitar, or searching for the world's best lobster roll.

Recent Posts

Cell Preparation Tips for Accurate Flow Cytometry Data

Generating accurate flow cytometry data requires more than just specific and sensitive antibodies validat...
Andrea Tu, PhD Nov 6, 2024

500 Antibodies & Counting: Accelerating Discovery with CST Antibodies Validated for Simple Western Technology

Since 2022, Cell Signaling Technology (CST) and Bio-Techne have been working together to bring best-in-cl...
Chris LaBreck, PhD Oct 23, 2024

Menin-KMT2A Inhibitors: A Promising Approach to Acute Myeloid Leukemia (AML) Treatment

Accounting for about 80% of adult acute leukemias, acute myeloid leukemia (AML) is an aggressive form of ...
Homa Rahnamoun, PhD Oct 16, 2024